Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myeloid, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Leukemia, Hairy Cell 1Leukemia 1

Interventions

fludarabine phosphate 19Cyclophosphamide 18Peripheral Blood Stem Cell Transplantation 17Tacrolimus 13Mycophenolic Acid 11Whole-Body Irradiation 10Busulfan 10Antilymphocyte Serum 9Methotrexate 8Cyclosporine 8Filgrastim 7Etoposide 6Radiotherapy 4Methylprednisolone 4Melphalan 4Carboplatin 4fludarabine 3Flow Cytometry 3liposomal amphotericin B 2aldesleukin 2Transplantation 2Topotecan 2Thiotepa 2Prednisone 2Polymerase Chain Reaction 2Ondansetron 2Morphine 2Leucovorin 2Interferon-alpha 2Fentanyl 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thrombocythemia, Essential × ON 01910 × Lymphoid × Clear all
NCT01167166 2017-06-26

Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)

Traws Pharma, Inc.

Phase 1/2 Completed
30 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡